EUVIMEDEUVIMED entdecken
Vergleichsstudie

Decreased Nonmelanoma Skin Cancer Risk With Interleukin-17 and Interleukin-23 Inhibitors Versus TNF-α Inhibitors in Psoriasis

Brad R Woodie, Justin A Freking, Gabrielle M Rivin, Alan B Fleischer

Journal of Drugs in Dermatology · 2026

DOI: 10.36849/jdd.9449 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Drugs in Dermatology, 2026. Verfasst von Brad R Woodie und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Psoriasis, Interleukin-17, Interleukin-23, Tumor Necrosis Factor-alpha.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisInterleukin-17Interleukin-23Tumor Necrosis Factor-alphaSkin NeoplasmsImmunosuppressive AgentsHumansFemaleNon-Melanoma Skin NeoplasmsMaleMiddle AgedCyclosporineAdultRisk FactorsAgedMethotrexate

Substanzen

Interleukin-17Interleukin-23Tumor Necrosis Factor-alphaCyclosporineImmunosuppressive AgentsMethotrexate

Zitieren

APA

Woodie, B. R., Freking, J. A., Rivin, G. M., & Fleischer, A. B. (2026). Decreased Nonmelanoma Skin Cancer Risk With Interleukin-17 and Interleukin-23 Inhibitors Versus TNF-α Inhibitors in Psoriasis. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.9449

Vancouver

Woodie BR, Freking JA, Rivin GM, Fleischer AB. Decreased Nonmelanoma Skin Cancer Risk With Interleukin-17 and Interleukin-23 Inhibitors Versus TNF-α Inhibitors in Psoriasis. Journal of Drugs in Dermatology. 2026. doi:10.36849/jdd.9449

BibTeX
@article{Woodie2026,
  author = {Woodie, Brad R and Freking, Justin A and Rivin, Gabrielle M and Fleischer, Alan B},
  title = {Decreased Nonmelanoma Skin Cancer Risk With Interleukin-17 and Interleukin-23 Inhibitors Versus TNF-α Inhibitors in Psoriasis},
  journal = {Journal of Drugs in Dermatology},
  year = {2026},
  doi = {10.36849/jdd.9449}
}
Kostenlos starten →